


PHARMACEUTICAL 2017

Axsome Therapeutics Inc. Rank 196 of 313





PHARMACEUTICAL 2017

Axsome Therapeutics Inc. Rank 196 of 313

The relative strengths and weaknesses of Axsome Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Axsome Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 167% points. The greatest weakness of Axsome Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 161% points.

The company's Economic Capital Ratio, given in the ranking table, is -316%, being 100% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	37,999
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,171
Liabilities, Non-Current	9,470
Other Assets	113
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	342
Property and Equipment	101
Research and Development	21,200
Revenues	0
Selling, General and Administrative Expense	6,344

Output Variable	Value in 1000 USD
Assets	38,213
Liabilities	16,641
Expenses	27,544
Stockholders Equity	21,571
Net Income	-27,202
Comprehensive Net Income	-27,202
Economic Capital Ratio	-316%